Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13100)	1/8/1998 5:24:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

Cheat sheet below. Maybe it is a form of skin lymphoma the poster was talking about. Do they have compassionate use for drgus for indications that are not in trials? Potential Markets TargretinTM (LGD1069): NEW PATIENTS PER YEAR (U.S.) Actinic keratoses: 1.5 million Diabetes (Type II): 15 million (total patients) Head and neck cancer: 39,750 Kaposi's sarcoma: 22,200 Lung cancer: 169,900 Ovarian cancer: 26,600 Prostate cancer: 244,000 Skin lymphoma: 6,000 PanretinTM* (ALRT1057): NEW PATIENTS PER YEAR (U.S.) APL: 2,500 Breast cancer: 182,000 Kaposi's sarcoma: 22,200 Ovarian cancer: 26,600 Prostate cancer: 244,000 Severe psoraisis: 157,000